Tracking eye-drop use with CONNECTDROP® for people with glaucoma
Official title: Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®: the GRANITE Study (Glaucoma tReatment AdhereNce wIth connecTed dEvice in Italy)
Run by Laboratoires Thea · NCT07206628 · Data updated 2026-11-12
This project will try using the CONNECTDROP® smart device and smartphone app to track daily eye-drop use in adults with open-angle glaucoma to measure how well they follow their prescribed treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Laboratoires Thea Industry-sponsored |
| Locations | 15 sites (Bologna and 14 other locations) |
| Status | Recruiting |
| Started | September 19, 2025 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT07206628 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with bilateral open-angle glaucoma who have been using a single IOP-lowering eye drop in an EASYGRIP® bottle for at least six weeks and who are willing to use the CONNECTDROP® device and smartphone app are ideal candidates.
✕Probably not a fit
Patients who are pregnant or lactating, on other chronic ocular treatments, unable or unwilling to use a smartphone-connected device, or unable to attend one of the study sites are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a national, multicenter, prospective observational study in which adults with bilateral open-angle glaucoma who are on a single IOP‑lowering eye drop in an EASYGRIP® bottle will use the CONNECTDROP® device and companion smartphone app daily. The main outcome is the mean annual adherence rate (percentage of prescribed doses taken) and the individual adherence profiles over time. The study will link objective adherence data from the device with clinical information to explore associations between adherence and clinical status. Pregnant or lactating people and those receiving other chronic ocular instillations are excluded from participation.
Why it matters
Potential benefit: If successful, the device could help clinicians identify patients who miss doses and enable targeted support to improve treatment adherence and potentially better IOP control.
How similar studies have gone: Similar connected-device and smartphone approaches have shown feasibility and some improvements in adherence in glaucoma and other chronic conditions, but results have been variable and not uniformly conclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥ 18 years old), man or woman * Patient with a diagnosis of bilateral open angle glaucoma or OHT * Patients being prescribed with glaucoma eye drops in EASYGRIP® bottle for at least 6 weeks in monotherapy. * Patient willing to participate in the study * Patient who consents for data collection in the frame of the study Exclusion Criteria: * Pregnant and/or lactating woman * Patient receiving another ocular treatment for a chronic condition (i.e. regular instillations for several months) * Protected patient: adult under guardianship, curatorship or other protection legal, deprived of liberty by judicial or administrative decision
Where it's running
-
Studio Oculistico D'Azeglio
Bologna, Italy Recruiting -
Centro Medico Polispecialistico Di Maita
Catania, Italy Recruiting -
Studio Medico Oculistico Dr.ssa Rosa SCHIAVELLI s.r.l.
Corigliano, Italy Recruiting -
Ospedale Policlinico S. Martino-IRCCS Clinica Oculistica Università di Genova
Genova, Italy Recruiting -
Centro Corporis Lab
Lecce, Italy Recruiting -
Studi Oculistici - Dott. Andrea Bedei
Lucca, Italy Recruiting
Show 9 more locations
-
Poliambulatorio Chirurgico Modenese Eyecare Clinic
Modena, Italy Recruiting -
Centro Oculistico Ramovecchi S.r.l.
Morrovalle, Italy Recruiting -
Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli studi di Napoli Federico II
Naples, Italy Recruiting -
UOSD di Oculistica, Fondazione PTV Policlinico Tor Vergata
Roma, Italy Recruiting -
IRCCS Fondazione G.B. Bietti
Roma, Italy Recruiting -
Ospedale San Donà Piave, Aussl 4 Veneto Orientale, UOC Oculistica
San Donà di Piave, Italy Recruiting -
AOU Sassari Clinica Oculistica
Sassari, Italy Recruiting -
Humanitas Gradenigo U.O. Oculistica
Torino, Italy Recruiting -
Ambulatorio Oculistica Ospedale San Carlo di Nancy -GVM-
Roma, Italy Not yet recruiting
Study contacts
- Study coordinator: Medical Operation Manager
- Email: Fabienne.HESKIA@theapharma.com
- Phone: +33 4 73 98 14 36
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
T10430 eye drops to slow childhood myopia progression
We will test whether T10430 eye drops can slow worsening nearsightedness in children aged 6 to 11.
-
T1695 versus ciclosporin for moderate to severe vernal keratoconjunctivitis in children and teenagers
This study will test whether T1695 eye treatment works better and is as safe as ciclosporin for kids and teens (ages 4–17) with moderate to severe vernal keratoconjunctivitis.
-
Sepofarsen injections for LCA10 due to the CEP290 p.Cys998X mutation
This study will test whether sepofarsen eye injections can improve vision in children and adults with LCA10 caused by the CEP290 c.2991+1655A>G (p.Cys998X) mutation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.